Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss

Key Points

• The study aims to identify oncogenic pathways and drug vulnerabilities linked to PTEN-loss in prostate cancer tumoroids.
• Development of a biobank utilizing genetically defined murine prostate cancer tumoroids
• Analysis of oncogenic pathways associated with PTEN-loss
• Evaluation of drug vulnerabilities using the tumoroids
• Uncovered specific oncogenic pathways activated by PTEN-loss
• Identified potential drug vulnerabilities in prostate cancer cells
• Suggests new therapeutic targets for treatment